## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 7.1% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($339.70)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: Fox 59 | 20251209T160742 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (ELV) concerning potential corporate wrongdoing by the company and its officers/directors. The firm encourages investors who purchased Elevance securities before April 18, 2024, and still hold them, to contact them for more information and to assist in the investigation. The representation of investors in class actions is on a contingency fee basis with no upfront cost to the investors.

**2. Elevance Health (NYSE: ELV) appoints Amy Schulman to board, joining Audit and Finance panels**
- Source: Stock Titan | 20251210T213139 | Bullish | Relevance: 99%
-  Elevance Health (NYSE: ELV) has appointed Amy Schulman, a distinguished healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will bring extensive expertise in healthcare innovation, regulatory strategy, and value creation to the company's Audit and Finance Committees. This appointment aligns with Elevance Health's strategy to enhance its board with diverse, independent, and forward-thinking leadership.

**3. Elevance Health appoints healthcare executive Amy Schulman to board**
- Source: Investing.com | 20251210T220810 | Bullish | Relevance: 99%
-  Elevance Health (NYSE:ELV) has appointed healthcare executive and venture capital leader Amy Schulman to its board of directors, effective January 12, 2026. Schulman, currently a Managing Partner at Polaris Partners, will serve on the companyâ€™s Audit and Finance Committees. This appointment aligns with Elevance Health's strategy for diverse and independent leadership.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: WRBL | 20251211T160758 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV) and its officers/directors. The firm is encouraging stockholders who purchased Elevance securities prior to April 18, 2024, and continue to hold them, to inquire about the securities investigation. The investigation aims to determine if there are grounds for a class action lawsuit, with no cost to investors unless the firm is successful in recovering funds.

**5. Elevance Health appoints healthcare executive Amy Schulman to board By Investing.com**
- Source: Investing.com UK | 20251210T220807 | Bullish | Relevance: 99%
-  Elevance Health announced the appointment of Amy Schulman, a healthcare executive and venture capital leader, to its board of directors, effective January 12, 2026. Schulman will serve on the company's Audit and Finance Committees. This appointment aligns with Elevance Health's board refreshment strategy to ensure diverse and independent leadership.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +8.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $81.1B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 13.2 |
| Current P/E | 12.0 |
| YoY Growth | -9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.9% to 7.1% (+8.9% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (7.1% > 6.0%), caution on chasing. MRS_5 at 6.4% confirms short-term momentum alignment. Outperforming sector by 9.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.58), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 7.07% (CS: 95) | Strong |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 2.58 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.007x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $360.22
- **Stop Loss:** $339.70 (5.7% risk)
- **Target:** $380.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $24,134.74
- **Portfolio %:** 24.13%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*